NCT05924958View on ClinicalTrials.gov

Clinical Study on the Immunomodulatory Effect of Eprolidone on Patients With Chronic Heart Failure

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

800

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

August 1, 2026

Study Completion Date

September 1, 2026

Conditions

Chronic Heart Failure Patients

Interventions

DRUG

Eprolidone

This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.

All Listed Sponsors

collaborator

First Affiliated Hospital of Xinjiang Medical University

OTHER

lead

Cheng LuFeng,Principal Investigator

OTHER

NCT05924958 - Clinical Study on the Immunomodulatory Effect of Eprolidone on Patients With Chronic Heart Failure | Biotech Hunter | Biotech Hunter